Please login to the form below

Not currently logged in
Email:
Password:

KRAS mutation

This page shows the latest KRAS mutation news and features for those working in and with pharma, biotech and healthcare.

Green light for Amgen’s KRAS inhibitor in the UK

Green light for Amgen’s KRAS inhibitor in the UK

NSCLC) with the KRAS G12C mutation. ... The drug’s adoption by NHS follows a 40-year search for a treatment for the mutation on the KRAS gene, present in a quarter of all tumours.”.

Latest news

  • Amgen aims for first KRAS inhibitor approval in the US Amgen aims for first KRAS inhibitor approval in the US

    In NSCLC, KRAS G12C is the most common KRAS mutation, with around 13% of patients with NSCLC in the US carrying this particular mutation. ... Data from the phase 1 trial found that seven (53%) of 13 experienced NSCLC patients with the KRAS G12C mutation

  • Pfizer signs $507m cancer deal with Effector Therapeutics Pfizer signs $507m cancer deal with Effector Therapeutics

    This includes patients with any KRAS mutation, amplifications or fusions in HER2, ERBB3, FGFR1 or FGFR2 receptor tyrosine kinases.

  • Merck strengthens KRAS stake with Taiho and Astex partnership Merck strengthens KRAS stake with Taiho and Astex partnership

    Another company looking to crack the KRAS mutation is Amgen, which recently announced some positive data for its pathfinder KRAS inhibitor AMG 510 in KRAS G12C-positive NSCLC. ... Other competitors in the KRAS inhibitor race include Mirati, Boehringer

  • Amgen reveals more data on KRAS drug Amgen reveals more data on KRAS drug

    It is estimated that around 14% of NSCLC adenocarcinoma patients and roughly 5% of colorectal cancer patients have the KRAS G12C mutation. ... Amgen is leading the field among companies developing inhibitors of KRAS, an oncogene that is implicated in

  • Boehringer bolsters KRAS push with $720m Lupin deal Boehringer bolsters KRAS push with $720m Lupin deal

    Once considered all-but ‘undruggable’, there are signs of progress in the KRAS field, with Amgen reporting encouraging anti-tumour activity with its  AMG 510 candidate – which targets a KRAS mutation ... the hope of providing “more effective and

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    This includes people with NSCLC who have a mutated KRAS gene - an area where no specific treatment option exists. ... With selumetinib you've now got that plus another 20-25 per cent of NSCLC cases - people with the KRAS mutation.”.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...